Drugs Made In America Acquisition (DMAAR) Cash from Investing Activities (2025)

Drugs Made In America Acquisition (DMAAR) posted Cash from Investing Activities of -$231.2 million for Q1 2025.

Drugs Made In America Acquisition (DMAAR) Cash from Investing Activities (2025) Analysis & Trends

Drugs Made In America Acquisition's Cash from Investing Activities history runs 1 years deep, the most recent figure standing at -$231.2 million for Q1 2025.

  • Quarterly Cash from Investing Activities changed N/A year-over-year to -$231.2 million in Q1 2025, while the trailing twelve-month figure through Dec 2025 was -$231.2 million (changed N/A YoY) and the FY2025 annual result came in at -$231.2 million, changed N/A from the prior year.
  • Cash from Investing Activities was -$231.2 million for Q1 2025 at Drugs Made In America Acquisition.
  • Across five years, Cash from Investing Activities topped out at -$231.2 million in Q1 2025 and bottomed at -$231.2 million in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 SIM Acquisition Corp. I 314.52 Mn 314.52 Mn - -
2 Thayer Ventures Acquisition 208.29 Mn 208.29 Mn - -
3 Newbury Street II Acquisition 185.26 Mn 185.26 Mn - -
4 Dynamix 179.36 Mn 179.36 Mn - -
5 Hallmark Venture 103.01 Mn 102.76 Mn - -
6 Voyager Acquisition 99.58 Mn 99.45 Mn - -
7 Gores Holdings X 95.80 Mn 95.37 Mn - 30,537.00
8 Archimedes Tech SPAC Partners 89.67 Mn 89.67 Mn - -
9 Marblegate Capital 81.65 Mn 55.81 Mn - -24.33 Mn
10 Drugs Made In America Acquisition 1.37 Mn 1.37 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2025 -231.15 Mn
Mar 31, 2025 -231.15 Mn